Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rentokil
RTO
|
+$514M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$210M |
| 3 |
TFI International
TFII
|
+$145M |
| 4 |
Ambev
ABEV
|
+$142M |
| 5 |
Vanguard S&P 500 ETF
VOO
|
+$133M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$8.38B |
| 2 |
Apple
AAPL
|
+$5.7B |
| 3 |
Amazon
AMZN
|
+$3.72B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.64B |
| 5 |
Mastercard
MA
|
+$3.47B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.11% |
| 2 | Healthcare | 21.42% |
| 3 | Financials | 11.42% |
| 4 | Industrials | 10.73% |
| 5 | Consumer Discretionary | 10.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2351
Century Aluminum
CENX
$4.44B
| $89.5K | ﹤0.01% |
10,956
-10,956
| -50% | -$82.8K |
|
2352
indie Semiconductor
INDI
$668M
| $89.3K | ﹤0.01% |
15,322
-15,322
| -50% | -$113K |
|
2353
Accel Entertainment
ACEL
$973M
| $87.5K | ﹤0.01% |
11,370
-11,370
| -50% | -$97.6K |
|
2354
Atea Pharmaceuticals
AVIR
$379M
| $87.2K | ﹤0.01% |
18,140
-18,138
| -50% | -$91.8K |
|
2355
AvePoint
AVPT
$2.72B
| $87.1K | ﹤0.01% |
21,209
-21,209
| -50% | -$90.8K |
|
2356
Caribou Biosciences
CRBU
$150M
| $86K | ﹤0.01% |
13,678
-13,676
| -50% | -$122K |
|
2357
Aurinia Pharmaceuticals
AUPH
$1.93B
| $85.3K | ﹤0.01% |
19,712
-19,712
| -50% | -$114K |
|
2358
AtaiBeckley Inc
ATAI
$2.66B
| $84.3K | ﹤0.01% |
31,939
-31,939
| -50% | -$97K |
|
2359
Bionano Genomics
BNGO
$12.2M
| $82.4K | ﹤0.01% |
94
-95
| -50% | -$120K |
|
2360
Vanda Pharmaceuticals
VNDA
$312M
| $82.3K | ﹤0.01% |
11,146
-11,146
| -50% | -$109K |
|
2361
Nektar Therapeutics
NKTR
$2.41B
| $82.3K | ﹤0.01% |
2,432
-2,431
| -50% | -$118K |
|
2362
IonQ
IONQ
$13.4B
| $80.2K | ﹤0.01% |
23,293
-23,297
| -50% | -$112K |
|
|
ME
2363
DELISTED
23andMe Holding Co
ME
| $80.2K | ﹤0.01% |
1,861
-1,861
| -50% | -$108K |
|
|
RDFN
2364
DELISTED
Redfin
RDFN
| $80.2K | ﹤0.01% |
18,940
-18,940
| -50% | -$89.1K |
|
|
AGEN
2365
Agenus
AGEN
$329M
| $80.1K | ﹤0.01% |
1,704
-1,704
| -50% | -$86.6K |
|
|
VTNR
2366
DELISTED
Vertex Energy, Inc
VTNR
| $79.7K | ﹤0.01% |
+12,887
| New | +$96.2K |
|
2367
Carvana
CVNA
$44B
| $79.2K | ﹤0.01% |
83,590
-98,600
| -54% | -$208K |
|
|
KZR
2368
DELISTED
Kezar Life Sciences
KZR
| $79.1K | ﹤0.01% |
1,124
-1,123
| -50% | -$83.3K |
|
|
GLDD
2369
DELISTED
Great Lakes Dredge & Dock
GLDD
| $78.6K | ﹤0.01% |
13,224
-13,224
| -50% | -$93K |
|
2370
Outdoor Holding Co
POWW
$247M
| $78K | ﹤0.01% |
45,001
-46,495
| -51% | -$117K |
|
|
EB
2371
DELISTED
Eventbrite
EB
| $77.8K | ﹤0.01% |
13,263
-13,263
| -50% | -$86.7K |
|
|
SGMO
2372
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $77.5K | ﹤0.01% |
24,731
-24,731
| -50% | -$96K |
|
2373
Riot Platforms
RIOT
$8.36B
| $77.5K | ﹤0.01% |
22,885
-22,885
| -50% | -$118K |
|
2374
Gevo
GEVO
$372M
| $77K | ﹤0.01% |
40,428
-40,428
| -50% | -$85.3K |
|
2375
GoodRx Holdings
GDRX
$1.07B
| $76.9K | ﹤0.01% |
16,519
-16,517
| -50% | -$81.4K |
|
Similar funds
Janus Henderson Group's Q4 2022 Portfolio in Review
As of Q4 2022, Janus Henderson Group held 2,666 positions worth $140B, down 48% from $267B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Janus Henderson Group withdrew a net $148B in Q4 2022, closing 210 positions and reducing 1,907 holdings. Its most notable exit was Terminix Global Holdings, Inc., an estimated $901M position sold in full.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 30% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Janus Henderson Group opened a new position in Rentokil worth $510M.
- Janus Henderson Group's largest Q4 2022 buy was Rentokil: 16,564,405 shares worth $510M.
- Janus Henderson Group added most to Apellis Pharmaceuticals in Q4 2022, an estimated $210M increase.
- Janus Henderson Group's biggest Q4 2022 reduction was Microsoft, cutting an estimated $8.38B.
- Janus Henderson Group fully exited Terminix Global Holdings, Inc. in Q4 2022, selling an estimated $901M.
- Janus Henderson Group's ten largest holdings make up 22% of its $140B portfolio in Q4 2022.
- Janus Henderson Group opened 131 new positions and closed 210 in Q4 2022.
- Janus Henderson Group's portfolio value fell 48% quarter-over-quarter to $140B.
Based on Janus Henderson Group's 13F filing for Q4 2022, filed 14 Feb 2023.